Sequential Intravesical Gemcitabine and Docetaxel Versus Repeat BCG‐Based Salvage After Prior BCG Failure in High‐Risk Non–Muscle‐Invasive Bladder Cancer: A Systematic Review and Meta‐Analysis
International Journal of Clinical Practice · 2026-01 · 2026 (1)
DOI: 10.1155/ijcp/4638501 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Clinical Practice, online erschienen am 29.07.2026. Verfasst von Jingpeng Liu und 7 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Tian Tan Hospital, Capital Medical University.
Abstract (Originalsprache)
Objectives
To compare sequential intravesical gemcitabine and docetaxel (Gem/Doce) with repeat BCG‐based intravesical salvage after prior BCG failure in high‐risk non–muscle‐invasive bladder cancer (NMIBC).
Methods
PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library were searched from inception to 20 January 2026. Comparative studies enrolling adults with high‐risk NMIBC after prior BCG exposure or failure were eligible if they compared sequential Gem/Doce with repeat BCG‐based intravesical therapy. Prior BCG status was extracted according to the source‐study definitions. The primary outcome was landmark recurrence. Secondary or exploratory outcomes included recurrence‐related time‐to‐event endpoints, radical cystectomy, progression, cancer‐specific survival, and adverse events. When time‐point data were not tabulated, prespecified landmark estimates were digitized from published Kaplan–Meier curves. Risk of bias was assessed with ROBINS‐I and certainty of evidence with GRADE.
Results
Three retrospective comparative cohorts involving 605 patients met the inclusion criteria. Of these, 299 patients (49.4%) were enrolled in an FDA‐defined BCG‐unresponsive cohort, whereas 306 patients (50.6%) were BCG‐exposed patients with recurrent disease after initial/single induction BCG rather than FDA‐defined BCG‐unresponsive disease. There was no significant difference in recurrence at 12 months (risk ratio [RR] 0.90, 95% confidence interval [CI] 0.60–1.34; I 2 = 72%). At 24 months, Gem/Doce was associated with lower recurrence (RR 0.77, 95% CI 0.63–0.94; I 2 = 0%), which represented the clearest pooled signal. An exploratory pooled hazard ratio for recurrence‐related survival was not significant (HR 0.95, 95% CI 0.77–1.18; I 2 = 0%) and should be interpreted cautiously because endpoint definitions differed across studies. Limited landmark data suggested fewer cystectomies with Gem/Doce at 24 months (RR 0.29, 95% CI 0.15–0.58). In the largest inverse probability of treatment weighted cohort, progression‐free, cystectomy‐free, and cancer‐specific survival were directionally favorable to Gem/Doce. Comparative safety reporting was sparse, but available data suggested less dysuria with Gem/Doce.
Conclusions
In selected patients pursuing bladder preservation after prior BCG failure, Gem/Doce was associated with more durable recurrence control than repeat BCG‐based intravesical salvage, with a concurrent signal for improved bladder preservation. However, only three retrospective studies could be included and they were heterogeneous with respect to prior BCG exposure; evidence for deeper oncological benefit therefore remains preliminary.
Förderung
- Beijing Tian Tan Hospital, Capital Medical University
Zitieren
APA
Liu, J., Wang, X., Zhou, Z., Yao, Z., Wang, Y., Zhang, B., Zhang, Y., & Zong, H. (2026). Sequential Intravesical Gemcitabine and Docetaxel Versus Repeat BCG‐Based Salvage After Prior BCG Failure in High‐Risk Non–Muscle‐Invasive Bladder Cancer: A Systematic Review and Meta‐Analysis. International Journal of Clinical Practice, 2026(1). https://doi.org/10.1155/ijcp/4638501
Vancouver
Liu J, Wang X, Zhou Z, Yao Z, Wang Y, Zhang B, et al. Sequential Intravesical Gemcitabine and Docetaxel Versus Repeat BCG‐Based Salvage After Prior BCG Failure in High‐Risk Non–Muscle‐Invasive Bladder Cancer: A Systematic Review and Meta‐Analysis. International Journal of Clinical Practice. 2026;2026(1). doi:10.1155/ijcp/4638501
BibTeX
@article{Liu2026,
author = {Liu, Jingpeng and Wang, Xiaoyan and Zhou, Zhongbao and Yao, Zhuoyue and Wang, Yulin and Zhang, Baining and Zhang, Yong and Zong, Huantao},
title = {Sequential Intravesical Gemcitabine and Docetaxel Versus Repeat BCG‐Based Salvage After Prior BCG Failure in High‐Risk Non–Muscle‐Invasive Bladder Cancer: A Systematic Review and Meta‐Analysis},
journal = {International Journal of Clinical Practice},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijcp/4638501}
}
EUVIMED